1432471-25-4

Basic information

• Product Name: (2S)-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-N^α-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]-N^ω-(8-propanoylamino-3,6-dioxaoctanoyl)argininamide
• CAS NO: 1432471-25-4
• Molecular Weight: 1097.28
• Mol File: 1432471-25-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (2S)-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-N^α-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]-N^ω-(8-propanoylamino-3,6-dioxaoctanoyl)argininamide(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-N^α-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]-N^ω-(8-propanoylamino-3,6-dioxaoctanoyl)argininamide(1432471-25-4)
• EPA Substance Registry System: (2S)-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)ethyl]-N^α-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]-N^ω-(8-propanoylamino-3,6-dioxaoctanoyl)argininamide(1432471-25-4)

Safety Data

• Hazardous Substances Data: 1432471-25-4(Hazardous Substances Data)

Upstream product

• 1432471-11-8 N-tert-butoxycarbonyl-N’-[8-(tert-butoxycarbonylamino-3,6-dioxa)octanoyl]-S-methylisothiourea 
• 108466-89-3 N-(tert-butyloxycarbonyl)-8-amino-3,6-dioxaoctanoic acid 
• 1432471-16-3 (2S)-N^ω-(8-amino-3,6-dioxaoctanoyl)-N-[2-(3,5-dioxo-1,2-diphenyl-1,2,4-triazolidin-4-yl)-ethyl]-N^α-[2-(1-{2-oxo-2-[4-(6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl)piperazin-1-yl]ethyl}cyclopentyl)acetyl]argininamide 
• 30364-55-7 succinimidyl propionate 

Relevant articles and documents

[3H]UR-PLN196: A Selective Nonpeptide Radioligand and Insurmountable Antagonist for the NeuropeptideY Y2Receptor

Radioing in on NPY: Attachment of a [2,3-3H]propionyl group through an appropriate linker to the guanidine group of an (S)-argininamide-type neuropeptideY (NPY) Y2 receptor antagonist resulted in a subtype-selective radioligand.